Birthright-Taglit Young Executive Forum Expresses Grave Concern Over Starbucks Union’s Endorsement of Violent Acts
TEL-AVIV, Israel–(BUSINESS WIRE)–The Birthright-Taglit Young Executive Forum, a robust assembly of CEOs and leaders from organizations collectively valued... Read more.
Vertex Energy Provides Operational Update for Third Quarter 2023
Conventional throughput volumes expected for the third quarter of 2023 of approximately 80,000 bpd to exceed previously forecasted 74,000-77,000 bpd range, reflecting... Read more.
Terran Orbital Opens New Printed Circuit Board Assembly Facility
Capacity to Assemble 5,000 Printed Circuit Boards per Month BOCA RATON, Fla.–(BUSINESS WIRE)–Terran Orbital (NYSE: LLAP), a global leader in satellite-based... Read more.
BlackRock Reports Third Quarter 2023 Earnings
NEW YORK–(BUSINESS WIRE)–BlackRock, Inc. (NYSE: BLK) today released its financial results for the third quarter of 2023. The company’s earnings release... Read more.
Defiance’s Suite of Daily Options (0DTE) Income ETFs, $QQQY & $JEPY, Surpass $100M AUM in less than 30 Days
MIAMI–(BUSINESS WIRE)–$JEPY #ETFs–Defiance ETFs, a pioneering force in the world of thematic and income-based exchange-traded funds (ETFs), is... Read more.
NW Natural Holdings Schedules Earnings Release and Conference Call for Friday, November 3
PORTLAND, Ore.–(BUSINESS WIRE)–Northwest Natural Holding Company (NYSE: NWN) (NW Natural Holdings) announced today it will issue its third quarter and... Read more.
Q4 DRAM Contract Prices Set to Rise, With Estimated Quarterly Increase of 3-8%, Says TrendForce
TAIPEI, Taiwan–(BUSINESS WIRE)–#DDR4—TrendForce reports indicate a universal price increase for both DRAM and NAND Flash starting in the fourth... Read more.
UnitedHealth Group Reports Third Quarter 2023 Results
Revenues of $92.4 Billion Grew 14% Year-Over-Year Earnings from Operations Grew 14% Cash Flows from Operations were $6.9 Billion Earnings were $6.24 Per Share, Adjusted... Read more.
LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023
NOT FOR UK USE – NOT INTENDED FOR UK MEDIA Phase 3 DELTA 2 results demonstrated that delgocitinib cream provided statistically significant improvements in both... Read more.
LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)
NOT FOR UK USE – NOT INTENDED FOR UK MEDIA A post hoc four-year interim subgroup analysis of the ongoing ECZTEND open-label extension trial assessed whether continuous... Read more.